Clinical Trial Update: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SAR408701 to docetaxel in CEACAM5-positive metastatic non-squamous non-small cell lung cancer has posted results and is not currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SAR408701

Snippet

Sponsor: Sanofi | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-01